Latest & greatest articles for enalapril

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on enalapril or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on enalapril and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for enalapril

21. Clinical and economic effects of replacing enalapril with benazepril in hypertensive patients

Clinical and economic effects of replacing enalapril with benazepril in hypertensive patients Clinical and economic effects of replacing enalapril with benazepril in hypertensive patients Clinical and economic effects of replacing enalapril with benazepril in hypertensive patients Briscoe T A, Dearing C J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Introduction of a programme aimed at encouraging treatment of hypertension using less costly angiotensin-converting-enzyme (ACE) inhibitors, namely, benazepril instead of enalapril for selected patients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Outpatients being treated for hypertension (using enalapril) who did

NHS Economic Evaluation Database.1996

22. A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia

A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia Butler J R, Fletcher P J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology ACE inhibitor enalapril maleate in the management of congestive heart failure. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients with overt congestive heart failure (CHF) in Australia. Setting Community and hospital. The study was carried out in Australia. Dates

NHS Economic Evaluation Database.1996

23. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure.

Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. 7950612 1994 12 09 1994 12 09 2013 11 21 0959-8138 309 6958 1994 Oct 01 BMJ (Clinical research ed.) BMJ Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. 833-7 To compare the ability of angiotensin converting enzyme inhibitors and beta blockers to slow the development of end stage renal failure in non-diabetic patients with chronic renal failure. Open (...) randomised multicentre trial with three year follow up. Outpatient departments of six French hospitals. 100 hypertensive patients with chronic renal failure (initial serum creatinine 200-400 mumol/l. 52 randomised to enalapril and 48 to beta blockers (conventional treatment). Enalapril or beta blocker was combined with frusemide and, if necessary, a calcium blocker or centrally acting drug in patients whose diastolic pressure remained above 90 mm Hg. 17 patients receiving conventional treatment and 10

BMJ1994 Full Text: Link to full Text with Trip Pro

24. Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes.

Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes. 8443481 1993 04 08 1993 04 08 2013 11 21 0959-8138 306 6871 1993 Jan 16 BMJ (Clinical research ed.) BMJ Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes. 175-82 To compare the effects of sodium depletion and of angiotensin I converting enzyme inhibition (...) on microalbuminuria in insulin dependent diabetes. Randomised, double blind, double dummy parallel study of normotensive diabetic patients with persistent microalbuminuria (30-300 mg/24 h) treated with enalapril or hydrochlorothiazide for one year after a three month, single blind placebo period. Diabetic clinic in a tertiary referral centre. 10 diabetic patients with low microalbuminuria (30-99 mg/24 h) and 11 with high microalbuminuria (100-300 mg/24 h). 11 subjects (six with low microalbuminuria, five

BMJ1993 Full Text: Link to full Text with Trip Pro

25. Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. The Quality-of-Life Hypertension Study Group.

Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. The Quality-of-Life Hypertension Study Group. 8446137 1993 04 05 1993 04 05 2013 11 21 0028-4793 328 13 1993 Apr 01 The New England journal of medicine N. Engl. J. Med. Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. The Quality-of-Life Hypertension Study Group. 907-13 We conducted a multicenter trial comparing two angiotensin-converting-enzyme inhibitors (...) to determine whether effects on quality of life during antihypertensive therapy are uniform within this pharmacologic class of agents, and to relate the effects of the drugs on quality of life to objective adverse events, such as the loss of a job or the death of a spouse. After a four-week washout period when they received placebo, 379 men with mild-to-moderately-severe hypertension were randomly assigned to receive captopril (25 to 50 mg twice daily, with or without hydrochlorothiazide) or enalapril (5

NEJM1993

26. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors.

Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. 1463530 1992 09 04 1992 09 04 2013 11 21 0028-4793 327 10 1992 Sep 03 The New England journal of medicine N. Engl. J. Med. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. 685-91 It is not known whether (...) the treatment of patients with asymptomatic left ventricular dysfunction reduces mortality and morbidity. We studied the effect of an angiotensin-converting--enzyme inhibitor, enalapril, on total mortality and mortality from cardiovascular causes, the development of heart failure, and hospitalization for heart failure among patients with ejection fractions of 0.35 or less who were not receiving drug treatment for heart failure. Patients were randomly assigned to receive either placebo (n = 2117

NEJM1992

27. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II)

Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II) 1495520 1992 09 04 1992 09 04 2013 11 21 0028-4793 327 10 1992 Sep 03 The New England journal of medicine N. Engl. J. Med. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (...) (CONSENSUS II) 678-84 Long-term administration of angiotensin-converting--enzyme (ACE) inhibitors has been shown to improve survival in patients with symptomatic left ventricular failure and to attenuate left ventricular dilatation in patients with myocardial infarction. We studied whether mortality could be reduced during the 6 months after an acute myocardial infarction with use of the ACE inhibitor enalapril. At 103 Scandinavian centers patients with acute myocardial infarctions and blood

NEJM1992

28. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis.

Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. 1458144 1993 01 13 1993 01 13 2013 11 21 0959-8138 305 6860 1992 Oct 24 BMJ (Clinical research ed.) BMJ Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: one year analysis. 981-5 To compare the efficacy, safety, and tolerance of enalapril and nifedipine in hypertensive patients with (...) non-insulin dependent diabetes. One year double blind follow up of patients randomly allocated to either enalapril or nifedipine with matching placebos for the alternative drug. Metabolic Investigation Unit, Hong Kong. 102 patients were randomised: 52 to nifedipine and 50 to enalapril. At baseline 44 patients had normoalbuminuria, 36 microalbuminuria, and 22 macroalbuminuria. Blood pressure, albuminuria, and parameters of renal function and glycaemic control. In patients who completed one year's treatment the median dose

BMJ1992 Full Text: Link to full Text with Trip Pro

29. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.

Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. 1359258 1992 12 17 1992 12 17 2015 06 16 0140-6736 340 8829 1992 Nov 14 Lancet (London, England) Lancet Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. 1173-8 An association between raised renin levels and myocardial infarction has been reported. We studied the effects of enalapril, an angiotensin-converting enzyme (ACE (...) ) inhibitor, on the development of myocardial infarction and unstable angina in 6797 patients with ejection fractions < or = 0.35 enrolled into the two Studies of Left Ventricular Dysfunction (SOLVD) trials. Patients were randomly assigned to placebo (n = 3401) or enalapril (n = 3396) at doses of 2.5-20 mg per day in two concurrent double-blind trials with the same protocol. Patients with heart failure entered the treatment trial (n = 2569) and those without heart failure entered the prevention trial (n = 4228). Follow-up

Lancet1992

30. Renal protective effect of enalapril in diabetic nephropathy.

Renal protective effect of enalapril in diabetic nephropathy. 1540729 1992 04 09 1992 04 09 2013 11 21 0959-8138 304 6823 1992 Feb 08 BMJ (Clinical research ed.) BMJ Renal protective effect of enalapril in diabetic nephropathy. 339-43 To determine whether inhibition of angiotensin converting enzyme can reduce the rate of decline in kidney function more than reducing blood pressure with other antihypertensive treatment. Prospective, open randomised study lasting a mean of 2.2 years in patients (...) with diabetic nephropathy. Three outpatient nephrology clinics. 40 patients with insulin dependent diabetes and diabetic nephropathy with reduced renal function. Antihypertensive treatment with enalapril or metoprolol, usually combined with frusemide. Rate of decline in glomerular filtration rate measured as chromium-51 edetic acid clearance. Glomerular filtration rate declined a mean of 2.0 (SD 3.2) ml/min/year in the group given enalapril and 5.6 (5.9) ml/min/year in the control group. The mean arterial

BMJ1992 Full Text: Link to full Text with Trip Pro

31. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators.

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. 2057034 1991 08 01 1991 08 01 2013 11 21 0028-4793 325 5 1991 Aug 01 The New England journal of medicine N. Engl. J. Med. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. 293-302 Patients with congestive heart failure have a high mortality rate (...) and are also hospitalized frequently. We studied the effect of an angiotensin-converting-enzyme inhibitor, enalapril, on mortality and hospitalization in patients with chronic heart failure and ejection fractions less than or equal to 0.35. Patients receiving conventional treatment for heart failure were randomly assigned to receive either placebo (n = 1284) or enalapril (n = 1285) at doses of 2.5 to 20 mg per day in a double-bind trial. Approximately 90 percent of the patients were in New York Heart

NEJM1991

32. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. 2057035 1991 08 01 1991 08 01 2013 11 21 0028-4793 325 5 1991 Aug 01 The New England journal of medicine N. Engl. J. Med. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. 303-10 To define better the efficacy of vasodilator therapy in the treatment of chronic congestive heart failure, we compared the effects (...) of hydralazine and isosorbide dinitrate with those of enalapril in 804 men receiving digoxin and diuretic therapy for heart failure. The patients were randomly assigned in a double-blind manner to receive 20 mg of enalapril daily or 300 mg of hydralazine plus 160 mg of isosorbide dinitrate daily. The latter regimen was identical to that used with a similar patient population in the effective-treatment arm of our previous Vasodilator-Heart Failure Trial. Mortality after two years was significantly lower

NEJM1991

33. Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease.

Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. 1932973 1991 12 17 1991 12 17 2013 11 21 0959-8138 303 6806 1991 Oct 05 BMJ (Clinical research ed.) BMJ Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease. 821-4 To compare the antihypertensive, renal haemodynamic and antiproteinuric effect of enalapril and atenolol in patients with proteinuria of non-diabetic (...) origin. Prospective, double blind, randomised 16 week study after a pretreatment period of at least three weeks. Outpatient nephrology and hypertension unit. 27 patients with proteinuria (greater than 300 mg protein/day) of non-diabetic origin, moderately impaired renal function (creatinine clearance 30-90 ml/min), and a pretreatment diastolic blood pressure of greater than 80 mm Hg. Treatment with enalapril (10 mg/day, adjusted between 5 and 40 mg, if necessary) or atenolol (50 mg/day, adjusted

BMJ1991 Full Text: Link to full Text with Trip Pro

34. Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy.

Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. 2337713 1990 06 18 1990 06 18 2013 11 21 0959-8138 300 6729 1990 Apr 07 BMJ (Clinical research ed.) BMJ Contrasting effects of enalapril and metoprolol on proteinuria in diabetic nephropathy. 904-7 To assess whether angiotensin converting enzyme inhibition reduces proteinuria in diabetic nephropathy more than blood pressure reduction with other antihypertensive treatment. Prospective, open randomised study (...) lasting eight weeks in patients with diabetic nephropathy. Outpatient nephrology clinics. 40 Patients with type I diabetes and diabetic nephropathy with reduced renal function. Antihypertensive treatment with enalapril or metoprolol, usually combined with frusemide. Arterial blood pressure and urinary excretion of albumin and protein. Arterial blood pressure after eight weeks was 135/82 (SD 13/7) mm Hg in the group given enalapril and 136/86 (16/12) mm Hg in the group given metoprolol. Proteinuria

BMJ1990 Full Text: Link to full Text with Trip Pro

35. Change in cough reflex after treatment with enalapril and ramipril.

Change in cough reflex after treatment with enalapril and ramipril. 2547470 1989 09 19 1989 09 19 2016 11 23 0959-8138 299 6690 1989 Jul 01 BMJ (Clinical research ed.) BMJ Change in cough reflex after treatment with enalapril and ramipril. 13-6 To find out whether enalapril or ramipril causes the sensitivity of the cough reflex to change or symptomatic cough to develop in patients with hypertension. Prospective, placebo controlled, double blind, randomised crossover study. Academic units (...) of clinical pharmacology and medicine. 20 Patients (nine men and 11 women) who needed to take angiotensin converting enzyme inhibitors to control hypertension. All patients received enalapril 10 mg daily, ramipril 10 mg daily, or placebo daily for one week in random order, with a washout period of at least one week between treatments. For assessment of sensitivity of the cough reflex the patients inhaled various concentrations of capsaicin solution in random order. Measurement of the doses of capsaicin

BMJ1989 Full Text: Link to full Text with Trip Pro

36. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria.

Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. 2848604 1989 01 25 1989 01 25 2013 11 21 0959-8138 297 6656 1988 Oct 29 BMJ (Clinical research ed.) BMJ Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. 1092-5 To assess the effectiveness of inhibition of angiotensin converting enzyme in preventing diabetic nephropathy. Randomised follow up study of normotensive diabetics with persistent (...) microalbuminuria (30-300 mg/24 hours) treated with enalapril or its matched placebo for one year. Double blind for first six months, single blind for last six months. Diabetic clinic in tertiary referral centre. Treatment group and placebo group each comprised 10 normotensive diabetics with persistent microalbuminuria. Treatment group was given enalapril 20 mg daily and controls matched placebo. Patients were given antihypertensive treatment after one year. Albumin excretion, arterial pressure, and renal

BMJ1988 Full Text: Link to full Text with Trip Pro

37. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group.

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. 2883575 1987 06 22 1987 06 22 2013 11 21 0028-4793 316 23 1987 Jun 04 The New England journal of medicine N. Engl. J. Med. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group (...) . 1429-35 To evaluate the influence of the angiotensin-converting-enzyme inhibitor enalapril (2.5 to 40 mg per day) on the prognosis of severe congestive heart failure (New York Heart Association [NYHA] functional class IV), we randomly assigned 253 patients in a double-blind study to receive either placebo (n = 126) or enalapril (n = 127). Conventional treatment for heart failure, including the use of other vasodilators, was continued in both groups. Follow-up averaged 188 days (range, 1 day to 20

NEJM1987

38. Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway.

Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway. 2870352 1986 05 16 1986 05 16 2015 06 16 0140-6736 1 8486 1986 Apr 19 Lancet (London, England) Lancet Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway. 872-5 Enalapril, atenolol, and hydrochlorothiazide were compared in a double-blind randomised parallel study (...) in general practice. 436 patients with mild to moderate hypertension were included at 76 centres. A two-week placebo run-in period was followed by 16 weeks of monotherapy. The initial doses were: enalapril 20 mg; atenolol 50 mg; and hydrochlorothiazide 25 mg. These were doubled if treatment was not effective after 4 weeks. Adverse reactions were the main reason for withdrawal from the study (9 on enalapril, 19 on atenolol, and 8 on hydrochlorothiazide). Systolic and diastolic blood pressures were

Lancet1986

39. Comparison of captopril and enalapril in patients with severe chronic heart failure.

Comparison of captopril and enalapril in patients with severe chronic heart failure. 3018566 1986 10 20 1986 10 20 2013 11 21 0028-4793 315 14 1986 Oct 02 The New England journal of medicine N. Engl. J. Med. Comparison of captopril and enalapril in patients with severe chronic heart failure. 847-53 To evaluate the concept that long duration of action is an advantageous property of angiotensin-converting enzyme inhibitors in the treatment of severe heart failure, we randomly assigned 42 patients (...) to therapy with either a short-acting inhibitor (captopril, 150 mg daily) or a long-acting inhibitor (enalapril, 40 mg daily) for one to three months while concomitant therapy with digoxin and diuretics was kept constant. The treatment groups had similar hemodynamic and clinical characteristics at base-line evaluation and similar initial responses to converting-enzyme inhibition. During long-term therapy, captopril and enalapril produced similar decreases in systemic blood pressure, but the hypotensive

NEJM1986